Senior Director, Investor Relations at Vir Biotechnology

San Francisco, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

BA/BS required, MBA, M.D., or relevant Ph.D. preferred
Minimum 10 years of investor relations experience in a publicly traded biotech or pharmaceutical company

Responsibilities

Develop and execute an annual investor relations strategy that effectively communicates Vir Bio’s short and long-term vision, corporate goals, and scientific progress to the investment community
Continuously monitor internal developments, external market events, and shareholder trends for Vir Bio and its peers to inform and adapt investor relations strategy, ensuring messaging and targeting remain relevant and impactful
Analyze shareholder base and investment trends for Vir Bio and its peers to inform investor targeting strategy, monitor its effectiveness, and identify proactive opportunities to engage with the investment community
Partner with executive leadership and cross-functional teams to ensure consistency and alignment of messaging and disclosure across all investor materials and presentations
Lead investor engagement activities, including organizing banking conferences, non-deal roadshows, R&D and analyst days, bus tours, and one-on-one meetings with the investment community, along with research or clinical investor events
Partner with the CFO as the main point of contact for sell-side analysts, actively engaging to convey Vir Bio’s strategy and key messages. Collect and assess sell-side models, compare them to internal forecasts, and use these insights to inform analyst and investor communications
Lead investor communications, including corporate presentation decks, management Q&As, website content, the business section of Form 10-K, and other matters as required
Prepare earnings releases and investor conference call scripts and coach leaders for effective delivery
Contribute to Board materials, other company press releases, and SEC documents (e.g., Form 8-Ks, Form S-3 filings)
Create briefing materials for management in preparation for investor meetings
Collaborate with cross-functional partners—including Competitive Intelligence, legal, and corporate communications—to monitor industry trends, ensure regulatory compliance, deliver key events like the annual stockholder meeting, and maintain accurate, consistent messaging across all external communications

Skills

Investor Relations

Strategic Communications

Financial Communication

Scientific Communication

Stakeholder Management

Market Analysis

Corporate Strategy

Vir Biotechnology

Develops monoclonal antibodies for infectious diseases

About Vir Biotechnology

Vir Biotechnology develops treatments that leverage the immune system to combat infectious diseases. The company uses a proprietary monoclonal antibody platform combined with machine learning to create a database of human antibodies, which aids in developing effective medicines. Their pipeline includes candidates for hepatitis B, hepatitis delta, HIV, and various viruses like influenza and COVID-19. Vir stands out by collaborating with industry leaders and organizations to accelerate scientific advancements, with the goal of transforming lives through innovative therapies.

San Francisco, CaliforniaHeadquarters

2016Year Founded

$640.6MTotal Funding

IPOCompany Stage

AI & Machine Learning, Biotechnology, HealthcareIndustries

501-1,000Employees

Benefits

Comprehensive healthcare coverage

Employer matched 401(k)

Employee stock purchase plan

Childcare assistance

Tuition reimbursement

Risks

Leadership instability due to key executive resignations may disrupt operations.

Job cuts and facility closures indicate potential financial strain.

Struggles to diversify beyond COVID-19 antibody success may impact revenue growth.

Differentiation

Vir Biotechnology uses AI-enhanced capabilities for monoclonal antibody development.

The company focuses on immune system manipulation for targeted therapies.

Vir's pipeline includes a potential functional cure for chronic hepatitis B.

Upsides

Increased interest in AI-driven drug discovery benefits Vir's AI capabilities.

The rise of personalized medicine aligns with Vir's monoclonal antibody focus.

Global pandemic preparedness funding supports Vir's broad-spectrum antiviral therapies.

Land your dream remote job 3x faster with AI

Try Jobo Free